Major Depressive Episode
68
16
18
31
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.8%
8 terminated out of 68 trials
79.5%
-7.0% vs benchmark
13%
9 trials in Phase 3/4
29%
9 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (68)
Major Depression and Messenger RNAs
tDCS: Sleep to Mood in Depression (S2M-D)
Personalized Ultrasonic Brain Stimulation for Depression (R61)
The RAFT ECT Study
Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE)
University of Iowa Interventional Psychiatry Service Patient Registry
Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder
Presynaptic Imaging in Major Depressive Episodes After COVID-19
A Text Messaging Intervention to Reduce Perinatal Depression Risk
At-Home tDCS as Maintenance Therapy
Terrorist Attack - Continuity of Care
Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients
The Impact of Coach-guided Risk Communication on the Risk of Major Depression
Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
Metabolomics During ElectroConvulsivoTherapy
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Microglial Activation in Inflammatory Bowel Disease
Neuroinflammation in COVID-19 and Depression